Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The HPV Vaccine Race

This article was originally published in RPM Report

Executive Summary

GlaxoSmithKline has some catching up to do in the race for what promises to be the world's biggest dollar-volume vaccine market. The company's human papilloma virus vaccine, Cervarix, is a year behind Merck's Gardasil in clinical development. The outcome of the race is by no means a foregone conclusion, however; development strategies, and how the social-conservative card plays out--will decide the winner in the newest vaccine market.

You may also be interested in...



Naloxone Could Go OTC

A House hearing on prescription abuse highlighted a potential OTC switch: naloxone for opioid overdose.

Novartis Bets Big on Meningitis:Wall Street Awaits Blockbuster Vaccine Franchise

Two years after shaking up the vaccine field with its big entry-acquisition of Chiron, Novartis AG has identified a make-or-break pair of projects in the meningitis area. The meningitis vaccines will determine whether the Novartis bet on vaccines will turn into a smart long-term diversification or a low-return move into an unfamiliar and unfriendly segment of health care.

How Wyeth Plans to Make Prevnar a $3 Billion Vaccine

Wyeth's conjugated pneumococcal vaccine continues to break records. The company boldly says there is a lot of growth left, enough to take the product through $3 billion a year and perhaps to $4.5 billion. No vaccine has ever reached those heights. Can Wyeth pull it off?

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS079624

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel